Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_001313913.2:c.198A>T

CA414435987

Gene: F9 (HGNC:2158)

Condition: hemophilia B (MONDO:0010604)

Inheritance Mode: X-linked inheritance

UUID: 8da5f010-6b77-4b3e-a9b8-895444c4c697

Approved on: 2026-04-10

Published on: 2026-04-10

HGVS expressions

NM_001313913.2:c.198A>T

NC_000023.11:g.139537119A>T

CM000685.2:g.139537119A>T

NC_000023.10:g.138619278A>T

CM000685.1:g.138619278A>T

NC_000023.9:g.138446944A>T

NG_007994.1:g.11384A>T

ENST00000218099.7:c.198A>T

ENST00000218099.6:c.198A>T

ENST00000394090.2:c.198A>T

ENST00000479617.2:n.205A>T

NM_000133.3:c.198A>T

NM_001313913.1:c.198A>T

NM_000133.4:c.198A>T

Pathogenic

PS4_Very Strong PM2_Supporting PP3

Evidence Links 0

Expert Panel

Coagulation Factor Deficiency VCEP

Criteria Specification Information

Criteria Specification: ClinGen Coagulation Factor Deficiency Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines for F9 Version 2.0.0

Criteria Specification Approval History

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Coagulation Factor Deficiency VCEP

The NM_000133.4(F9):c.198A>T; p.Glu66Asp variant is a missense variant in F9 that is absent from from gnomAD v4.1.0 (PM2_Supporting) and is predicted to have a deleterious effect (REVEL score of 0.908; PP3). The variant has been observed in at least eleven patients in the literature with moderate to severe hemophilia B, both with and without inhibitors (PMID:34880139, 11 points PS4, PS4_Very_Strong). In summary, this variant meets the criteria to be classified as pathogenic for hemophilia B. ACMG/AMP criteria applied, as specified by the Coagulation Factor Deficiency Variant Curation Expert Panel (specifications version 2.0.0) for F9: PS4_Very strong, PM2_Supporting, PP3.

PS4_Very Strong

This variant has been observed in at least 11 patients in the literature with moderate to severe hemophilia B, both with and without inhibitors (PMID:34880139, 11 points PS4, PS4_Very_Strong).

PM2_Supporting

This variant is absent from gnomAD v4.1.0 (PM2_Supporting).

PP3

This variant is predicted to have a deleterious effect (REVEL score of 0.908; PP3), which is greater than the Clingen CFD threshold for PP3 (>0.6), with splicing predicted to be unaffected (SpliceAI scores less than 0.1).

Curation History

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.